PTAB deals Bass another blow
PTAB shoots down Kyle Bass IPR request
Dacian G / Shutterstock.com
Hedge fund manager Kyle Bass’s Coalition for Affordable Drugs has suffered another setback in its bid to knock out allegedly spurious patents after the US Patent and Trademark Office (USPTO) declined to institute an inter partes review (IPR) of a patent owned by Biogen.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Kyle Bass; Coalition for Affordable Drugs; PTAB; USPTO; Biogen; Tecfidera; MS